Oncolytics Biotech (ONCY) Payables (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Payables data on file, last reported at $3.6 million in Q4 2025.

• On a quarterly basis, Payables fell 13.33% year-over-year to $3.6 million in Q4 2025; TTM through Dec 2025 was $3.6 million, a 13.33% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 15.06% from the prior year.
• Payables for Q4 2025 stood at $3.6 million, down from $5.2 million in the prior quarter.
• Over the last five years, Payables for ONCY reached as high as $7.3 million in Q3 2023 and fell as low as $1.6 million in Q4 2021.
• Historically, Payables has averaged $3.1 million across 5 years, with a median of $2.8 million in 2022.
• Across the five-year window, Payables soared 180.89% in 2023 and plunged 55.15% in 2024, its largest moves.
• Year by year, Payables stood at $1.6 million in 2021, then jumped by 69.41% to $2.7 million in 2022, then advanced by 0.86% to $2.8 million in 2023, then soared by 49.13% to $4.1 million in 2024, then declined by 13.33% to $3.6 million in 2025.
• Per Business Quant data, the three most recent Payables figures were $3.6 million in Q4 2025, $5.2 million in Q3 2025, and $4.6 million in Q2 2025.